Hallucinogen Use Disorders

Published:April 18, 2016DOI:https://doi.org/10.1016/j.chc.2016.03.006

      Keywords

      To read this article in full you will need to make a payment

      References

        • Carod-Artal F.
        Alucinógenos en las culturas precolombinas mesoamericanas.
        Neurologia. 2015; 30: 42-49
        • King L.A.
        • Kicman A.T.
        A brief history of “new psychoactive substances”.
        Drug Test Anal. 2011; 3: 401-403
        • Weaver M.F.
        • Hopper J.A.
        • Gunderson E.W.
        Designer drugs 2015: assessment and management.
        Addict Sci Clin Pract. 2015; 10: 8
        • Glennon R.A.
        Neurobiology of hallucinogens.
        in: Galanter M. Kleber H. The American psychiatric publishing textbook of substance abuse treatment. 4th edition. APPI, Washington, DC2008: 181-189
      1. National Institute on Drug Abuse. MDMA (Ecstasy or Molly). 2013. Available at: http://www.drugabuse.gov/publications/drugfacts/mdma-ecstasy-or-molly. Accessed September 24, 2015.

        • Substance Abuse and Mental Health Services Administration
        Results from the 2013 National Survey on drug use and health: summary of national findings. NSDUH Series H-48, HHS Publication No. (SMA) 14–4863.
        Substance Abuse and Mental Health Services Administration, Rockville (MD)2014: 1-143
      2. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The CBHSQ Report: a day in the life of young adults: substance use facts. Rockville (MD): 2014. p. 1–7.

      3. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN report: emergency department visits involving phencyclidine (PCP). Rockville (MD): 2013.

      4. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN report: ecstasy-related emergency department visits by young people increased between 2005 and 2011; Alcohol involvement remains a concern. Rockville (MD): 2013.

        • American Psychiatric Association
        Diagnostic criteria from DSM-5.
        American Psychiatric Publishing, Washington, DC2013
        • Johnston L.D.
        • Miech R.A.
        • O'Malley P.M.
        • et al.
        Use of alcohol, cigarettes, and number of illicit drugs declines among U.S. teens.
        University of Michigan News Service, Ann Arbor (MI)2014 (Available at:)
        • Wu P.
        • Liu X.
        • Hoang T.P.
        • et al.
        Ecstasy use among U.S. adolescents from 1999 to 2008.
        Drug Alcohol Depend. 2010; 112: 33-38
        • Palamar J.J.
        • Kamboukos D.
        An examination of sociodemographic correlates of ecstasy use among high school seniors in the United States.
        Subst Use Misuse. 2014; 49: 1774
        • Novins D.K.
        • Fickenscher A.
        • Manson S.M.
        American Indian adolescents in substance abuse treatment: diagnostic status.
        J Subst Abuse Treat. 2006; 30: 275-284
        • Brière F.N.
        • Fallu J.-S.
        • Janosz M.
        • et al.
        Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students.
        J Epidemiol Community Health. 2012; 66: 990-994
        • Wright N.E.
        • Strong J.A.
        • Gilbart E.R.
        • et al.
        5-HTTLPR genotype moderates the effects of past ecstasy use on verbal memory performance in adolescent and emerging adults: a pilot study.
        PLoS One. 2015; 10: e0134708
        • Kim J.
        • Fan B.
        • Liu X.
        • et al.
        Ecstasy use and suicidal behavior among adolescents: Findings from a national survey.
        Suicide Life Threat Behav. 2011; 41: 435-444
        • Strassman R.J.
        Hallucinogenic drugs in psychiatric research and treatment: perspectives and prospects.
        J Nerv Ment Dis. 1995; 183: 127-138
        • Taylor R.L.
        • Maurer J.I.
        • Tinklenberg J.R.
        Management of “bad trips” in an evolving drug scene.
        J Am Med Assoc. 1970; 213: 422-425
        • Abraham H.D.
        • McCann U.D.
        • Ricaurte G.A.
        Psychedelic drugs.
        in: Davis K.L. Charney D. Coyle J.T. Neuropsychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia2002: 1545-1556
      5. D’Orazio JL, Bassett R, Boroughf WL. Hallucinogen toxicity. 2015. Available at: http://emedicine.medscape.com/article/814848. Accessed October 8, 2015.

        • Tacke U.
        • Ebert M.H.
        Hallucinogens and phencyclidine.
        in: Kranzler H.R. Ciraulo D.A. Clinical manual of addiction psychopharmacology. American Psychiatric, Washington, DC2005: 211-241
        • Abraham H.D.
        Visual phenomenology of the LSD flashback.
        Arch Gen Psychiatry. 1983; 40: 884-889
        • Abraham H.D.
        • Mamen A.
        LSD-like panic from risperidone in post-LSD visual disorder.
        J Clin Psychopharmacol. 1996; 16: 228-231
        • Morehead D.B.
        Exacerbation of hallucinogen-persisting perception disorder with risperidone.
        J Clin Psychopharmacol. 1997; 17: 327-328
        • Schwarz C.J.
        e complications of LSD: a review of the literature.
        J Nerv Ment Dis. 1968; 146: 174-186
        • Strassman R.J.
        Adverse reactions for psychedelic drugs: a review of the literature.
        J Nerv Ment Dis. 1984; 172: 577-595
        • Halpern J.H.
        • Pope Jr., H.G.
        Hallucinogen persisting perception disorder: what do we know after 50 years?.
        Drug Alcohol Depend. 2003; 69: 109-119
        • Markel H.
        • Lee A.
        • Holmes R.D.
        • et al.
        LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents.
        J Pediatr. 1994; 125: 817-819
        • El-Mallakh R.S.
        • Halpern J.H.
        • Abraham H.D.
        Substance abuse: hallucinogen- and MDMA-related disorders (chapter 60).
        in: Tasman A. Maj M. First M.B. Psychiatry. 3rd edition. John Wiley & Sons, London2008: 1100-1126